1-5 of 5
Hubert Schrezenmeier
Close
Sort by
Journal Articles

AML with complex karyotype: extreme genomic complexity revealed by combined long-read sequencing and Hi-C technology

Marius-Konstantin Klever, Eric Sträng, Sara Hetzel, Julius Jungnitsch, Anna Dolnik, Robert Schöpflin, Jens-Florian Schrezenmeier, Felix Schick, Olga Blau, Jörg Westermann, Frank G. Rücker, Zuyao Xia, Konstanze Döhner, Hubert Schrezenmeier, Malte Spielmann, Alexander Meissner, Uirá Souto Melo, Stefan Mundlos, Lars Bullinger
Journal: Blood Advances
Blood Adv (2023) 7 (21): 6520–6531.
https://doi.org/10.1182/bloodadvances.2023010887
Published: 2023
Includes: Supplemental data
Journal Articles

Complement and platelets: prothrombotic cell activation requires membrane attack complex–induced release of danger signals

Marco Mannes, Veronika Pechtl, Susanne Hafner, Arthur Dopler, Oskar Eriksson, Vivek Anand Manivel, Lisa Wohlgemuth, David Alexander Christian Messerer, Hubert Schrezenmeier, Kristina N. Ekdahl, Bo Nilsson, Eva-Maria Jacobsen, Manfred Hoenig, Markus Huber-Lang, Christian K. Braun, Christoph Q. Schmidt
Journal: Blood Advances
Blood Adv (2023) 7 (20): 6367–6380.
https://doi.org/10.1182/bloodadvances.2023010817
Published: 2023
Includes: Supplemental data
Journal Articles

Deregulated expression of circular RNAs in acute myeloid leukemia

Susanne Lux, Tamara J. Blätte, Bernhard Gillissen, Antje Richter, Sibylle Cocciardi, Sabrina Skambraks, Klaus Schwarz, Hubert Schrezenmeier, Hartmut Döhner, Konstanze Döhner, Anna Dolnik, Lars Bullinger
Journal: Blood Advances
Blood Adv (2021) 5 (5): 1490–1503.
https://doi.org/10.1182/bloodadvances.2020003230
Published: 2021
Includes: Supplemental data
Journal Articles

Eculizumab in cold agglutinin disease (DECADE): an open-label, prospective, bicentric, nonrandomized phase 2 trial

Clinical Trials & Observations
Alexander Röth, Martin Bommer, Andreas Hüttmann, Dörte Herich-Terhürne, Nils Kuklik, Jan Rekowski, Veronika Lenz, Hubert Schrezenmeier, Ulrich Dührsen
Journal: Blood Advances
Blood Adv (2018) 2 (19): 2543–2549.
https://doi.org/10.1182/bloodadvances.2018024190
Published: 2018
Journal Articles

Ravulizumab (ALXN1210) in patients with paroxysmal nocturnal hemoglobinuria: results of 2 phase 1b/2 studies

Clinical Trials & Observations
Alexander Röth, Scott T. Rottinghaus, Anita Hill, Eric S. Bachman, Jin Seok Kim, Hubert Schrezenmeier, Louis Terriou, Álvaro Urbano-Ispizua, Richard A. Wells, Jun Ho Jang, Austin G. Kulasekararaj, Jeff Szer, Rasha Aguzzi, Andrew I. Damokosh, Lori Shafner, Jong Wook Lee
Journal: Blood Advances
Blood Adv (2018) 2 (17): 2176–2185.
https://doi.org/10.1182/bloodadvances.2018020644
Published: 2018
Includes: Supplemental data